Both in Pharmaceuticals
NewAmsterdam Pharma Company N.V vs Arcus Biosciences
Over the past year NAMS returned −47.1% and RCUS returned −7.8%; their daily moves had a correlation of 0.24.
NAMS −47.1% RCUS −7.8%Growth of $1, one year, split-adjusted
| Metric | NAMS | RCUS |
|---|---|---|
| Price | $20.06 | $18.19 |
| Market cap | $2.40B | $2.32B |
| Today | −3.37% | −2.26% |
| 1 month | −17.0% | −27.9% |
| 6 months | −29.4% | −29.2% |
| Year to date | −42.8% | −23.7% |
| 1 year | −44.0% | −10.3% |
| Revenue growth (YoY) | −80.7% | −74.4% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −1732.9% | −222.0% |
| P/E (TTM) | — | — |
| Price / sales | 336.7× | 19.8× |
| Net cash | $633.9M | $601.0M |
| Dividend yield | — | — |
| Volatility (60d) | 50.9% | 62.7% |
| Short % of float | 16.4% | 13.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).